Disguised Alpha   /   Compound references. Original research.
SLU-PP-332Research reference

SLU-PP-332 / Study library

Research, with context.

Filter by study model, then open the original record to examine methods and findings.

3 studies shown

STUDY 01 · 2023
Skeletal-muscle cell line and mice

Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity

The researchers reported changes in cellular respiration, oxidative muscle fibers, exercise-associated gene expression, and mouse treadmill endurance. Genetic experiments supported a role for ERRα in the endurance response.

Reading limit: These are cell and animal results. They do not establish human endurance improvement or show that exercise can be replaced.

↗
STUDY 02 · 2024
Lean mice and two mouse models of obesity

A Synthetic ERR Agonist Alleviates Metabolic Syndrome

The study reported shifts toward fat utilization and changes in energy expenditure and adiposity. In diet-induced obesity, glucose tolerance improved while the insulin-tolerance test did not show a change.

Reading limit: The response varied by endpoint and model. Mouse metabolic effects cannot establish a human weight-management outcome or validate a marketed formulation.

↗
STUDY 03 · 2023
Aged mice; supporting human and mouse tissue analyses

Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney

Researchers treated 21-month-old mice for eight weeks and reported changes in albuminuria, mitochondrial measures, inflammatory markers, and kidney-cell preservation. The findings connect ERR activity with several aging-related pathways.

Reading limit: The intervention was studied in mice. Human tissue comparisons in the paper are not a human treatment trial.

↗

How this guide was prepared

We reviewed the linked primary publications and source records for the claims summarized here. This is a focused educational selection, not a systematic review or a clinical recommendation. Scientific findings are kept separate from supplier catalog descriptions.

The selected evidence comes from laboratory and animal studies. It does not establish human efficacy, an appropriate human-use protocol, or the safety and performance of a commercial formulation. SLU-PP-332 and SLU-PP-915 are distinct molecules and should not be treated as interchangeable.

Source index

Identity and product documentation

Confirm molecular identity, batch identification, analytical methods and the actual formulation before relating a commercial material to a publication. A purity percentage alone does not establish all of those facts.

Visit Disguised Alpha or read the extended compound profile.